The estimated Net Worth of Jon R Duane is at least $859 ezer dollars as of 6 March 2024. Mr. Duane owns over 6,920 units of Ironwood Pharmaceuticals Inc stock worth over $526,472 and over the last 6 years he sold IRWD stock worth over $0. In addition, he makes $332,101 as Independent Director at Ironwood Pharmaceuticals Inc.
Jon has made over 1 trades of the Ironwood Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he bought 6,920 units of IRWD stock worth $60,204 on 6 March 2024.
The largest trade he's ever made was buying 6,920 units of Ironwood Pharmaceuticals Inc stock on 6 March 2024 worth over $60,204. On average, Jon trades about 865 units every 0 days since 2019. As of 6 March 2024 he still owns at least 121,028 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Mr. Duane stock trades at the bottom of the page.
Jon R. Duane is Independent Director of the Company. Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm's biotech practice. In that role, Mr. Duane advised both private and public companies in the pharmaceutical, medical device and life science industries, as well as academic research centers, on various strategic initiatives. Mr. Duane has served as the executive chair on the board of Nashville Biosciences since 2017. Mr. Duane graduated from Wesleyan University with a B.A. in government and received an M.B.A from Harvard Business School. Mr. Duane brings to the board of directors significant experience advising academic research centers and companies across the life science and medical device industries.
As the Independent Director of Ironwood Pharmaceuticals Inc, the total compensation of Jon Duane at Ironwood Pharmaceuticals Inc is $332,101. There are 8 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of $10,068,800.
Jon Duane is 61, he's been the Independent Director of Ironwood Pharmaceuticals Inc since 2019. There are 6 older and 10 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.
Jon's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts és Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include: